新氨基糖苷类抗生素89－07给药方案研究

用小鼠败血症系统感染模型，以感染小鼠肾匀浆活菌计数为标准，以庆大霉素为对照药，探讨日剂量单次与分两次给药两种方案对新氨基糖苷类抗生素８９—０７体内抗留作用的影响。结果表明大肠杆菌９０－０２０、绿脓假单胞菌３—３７４、金葡球菌９０—５０６对抗生素８９—０７和庆大霉素均敏感（ＭＩＣ范围０．０６２５～２ｍｇ／Ｌ）；抗生素８９—０７和庆大霉素日剂量单次给药组（ＯＤ）３株实验菌的肾匀浆活菌计数值由给药前的４．９４±０．０９、４．６０±０．２７、４．８６±０．１０１ｇｃｆｕ／ｍｌ分别降至１．９４±０．１９、１．８４±０．２５、１．８８±０．２５１ｇｃｆｕ／ｍｌ（给药后７～８ｈ）．日剂量分两次给药组（ＢＩＤ）则分别降至２．９５±０．４８、２．８７±０．３７、３．４４±０．２７１ｇｃｆｕ／ｍｌ。ＯＤ组对３株实验菌的最大杀菌作用Ｅｍａｘ分别为３．０２、２．９７和２．８５１ｇｃｆｕ／ｍｌ，ＯＤ给药方案的体内杀菌作用明显优于ＢＩＤ方案。     

Occurrence and Distribution of Bone Tumors in Beagle Dogs Exposed to 90Sr

Radiation-induced bone tumors in beagle dogs exposed to ⁹⁰Sr have been evaluated in terms of their incidence, time of appearance, occurrence as multiple tumors, anatomic distribution, and the influence of sex on their development. Among dogs fed ⁹⁰Sr during skeletal development, the incidence of bone tumors was dose dependent. Tumors thus appeared in 10 of 19 dogs receiving average skeletal doses of 130 Gy, 15 of 60 receiving 97 Gy, 5 of 61 receiving 61 Gy, 2 of 65 receiving 26 Gy, and 1 of 40 receiving 1.3 Gy. No tumors appeared among 66 dogs who received 8 Gy, 78 who received 0.3 Gy, and 80 non-irradiated controls, all of which have been observed for life. Among dogs given a single intravenous injection of ⁹⁰Sr in early adulthood, tumor production was somewhat higher than among ⁹⁰Sr-fed dogs at the same radiation dose: bone tumors were present in 6 of 25 dogs who received 62 Gy and 1 of 20 dogs who received 7.5 Gy. Bone tumors appeared sooner and were more often multiple in animals receiving the higher doses. Long bones were the sites of most of the tumors appearing after the highest dose level. Bones of the head, particularly the mandible, were the predominant site of tumors in the next highest dose level group.     

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

Forty-nine patients were treated with either 3×75 MBq ⁸⁹Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of ⁸⁹Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of ⁸⁹Sr therapy on life expectation.     

人血清免疫球蛋白工作标准的制备与标定

本文报导混合浓缩人血清工作标准(89-1)的制备和用WHO相应参考标准血清标定出其中五类免疫球蛋白(Igs)及IgG4亚类含量。该制剂主要用于体外测定IgG、IgA、IgM的工作标准,也可供作体外测定IgD、IgE、IgG4的工作标准。混合前每份血清均无乙型肝炎表面抗原、转氨酶正常。定量分装为每安瓿0.5ml,经冷冻干燥后,4℃保存。参照国际参考标准血清67/97及67/37,分别以免疫单扩散法标定89-1中IgG、IgA、ISM含量;以酶联免疫吸附试验(ELISA)标定IgD、IgG4和IgE含量。其中IgG、IgG4、IgA、IgM含量,应用本室制备的相应单克隆抗体(McAb)标定,而IgD和IgE应用多克隆抗体(PcAb)进行标定。并用五剂量法及四剂量法分别计算Igs含量。     

Pterygium excision with or without postoperative irradiation,a double-blind study

A double-blind study (covering 40 months) of 40 eyes with a pterygium which had not previously been operated on, was carried out to study the effect of postoperative irradiation. Nineteen eyes were treated by the bare sclera operation technique only and in 13 cases (68%) a recurrence occurred within 4 months. In 18 eyes from the group of patients treated with Sr 90 irradiation on the 1st, 7th and 14th postoperative day (maximum 3×1000 rad) no recurrences were seen.Patients with a recurrent pterygium and diplopia, symblepharon, visual disturbances (growth over the pupil or severe astigmatism) or many previous operations, were treated by lamellar keratoplasty (Dake, 1980). The recurrences without these complications were treated with success by the bare sclera technique and postoperative irradiation.Complications did not occur in any of the series.     

~(89)Sr治疗骨转移癌疼痛研究

 目的　评价放射性核素89锶 (89Sr)对骨转移癌的止痛疗效和不良反应 ,并探讨其在癌性骨痛治疗中的应用范围。方法　观察 35例骨转移癌患者使用89Sr治疗后的止痛疗效、肿瘤标记物水平的变化、不良反应及血液学毒副反应。结果　89Sr止痛总有效率为 71 .4 % ,其中来源于前列腺癌和乳腺癌的骨转移癌患者有效率达到 80 .0 %。少数肿瘤标记物水平有下降。副反应主要为轻度可逆性的骨髓造血功能损害。89Sr对血生化无明显不良影响。结论　89Sr是治疗骨转移癌疼痛的一种安全有效的方法     

早吸吮勤吸吮对早泌乳的影响

为了探讨产后半小时内早吸吮、勤吸吮对早泌乳的影响。选择１１６例足月妊娠孕产妇，分别在第二产程及产后半小时抽取母亲静脉血，采用放射免疫双抗法（ＤＡＲＩＡ）测定胎儿娩出前、吸吮后和未吸吮时，母亲血清垂体催乳素（ＰＲＬ）值。结果表明：第二产程时两组血清ＰＲＬ值无显著差异。而产后半小时早吸吮的母亲体内血清中ＰＲＬ水平明显高于未吸吮的血清ＰＲＬ值。早吸吮的母亲泌乳早。     

UV-LED用2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2+荧光粉

以SrCO3、BaCO3、H3BO3、Eu2O3和NH4H2PO4为原料,通过高温固相法,合成了2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2 荧光粉。通过XRD图谱、激发和发射光谱、光色参数和相对亮度的测量,研究了Ba2 对荧光粉的晶体结构以及发光性能的影响。结果表明:2(Sr,Ba)O-0.16B2O3-0.84P2O5:Eu2 荧光粉属于四方晶系,晶胞参数随Ba2 摩尔含量增加而增大。Ba2 的引入可以显著提高荧光粉的相对亮度,同时,随着Ba2 摩尔含量的增加,荧光粉的发射主峰向短波方向移动,出现蓝移,其色坐标y值逐渐减小,有利于提高白光发光二极管的流明效率和显色指数。     

89锶内照射治疗转移性骨肿瘤骨痛的临床观察

目的:分析89锶治疗转移性骨肿瘤的临床疗效及其安全性.方法:42例转移性骨肿瘤患者接受了89锶治疗.治疗后定期测定血常规、血生化等指标,随访时间3个月以上.对患者骨痛缓解情况、不良反应和血液学、肝肾功能变化进行观察和评价.结果:42例中有效35例,总有效率83.3%,起效时间2～20 d,缓解持续时间3～14个月.毒性反应主要有轻度可逆性骨髓抑制,血液学毒性小于Ⅱ级.无过敏反应及其他特殊不良反应.对肝肾功能无明显影响.结论:89锶对于转移性骨肿瘤所致的剧烈疼痛有良好的止痛效果,毒副作用小,是提高患者的生存质量的一种有效、安全的治疗方法.